

Table S29: Percent of IgG+ B cells that are GT8++ (regardless of KO binding status) magnitude testing between non-baseline time points for the treatment group, for frozen PBMC samples. Testing was done using Wilcoxon signed-rank test for paired data (two-sided,  $\alpha = 0.05$ ) and p values less than 0.05 are highlighted.

|                           | Number<br>of Pairs | Median (Range)                                      | P Value |
|---------------------------|--------------------|---|---------|
| <b>20µg</b>               |                    |   |         |
| Wk4 (V06) vs. Wk8 (V07)   | 18                 | 0.1264 [0.0528, 0.3482] vs. 0.0833 [0.0208, 0.2884] | 0.0001  |
| Wk4 (V06) vs. Wk10 (V08)  | 17                 | 0.1284 [0.0528, 0.3482] vs. 2.0403 [0.3117, 7.6517] | <0.0001 |
| Wk4 (V06) vs. Wk16 (V10)  | 18                 | 0.1264 [0.0528, 0.3482] vs. 0.5411 [0.1139, 1.7309] | <0.0001 |
| Wk8 (V07) vs. Wk10 (V08)  | 17                 | 0.0838 [0.0208, 0.2884] vs. 2.0403 [0.3117, 7.6517] | <0.0001 |
| Wk8 (V07) vs. Wk16 (V10)  | 18                 | 0.0833 [0.0208, 0.2884] vs. 0.5411 [0.1139, 1.7309] | <0.0001 |
| Wk10 (V08) vs. Wk16 (V10) | 17                 | 2.0403 [0.3117, 7.6517] vs. 0.5513 [0.1139, 1.7309] | <0.0001 |
| <b>100µg</b>              |                    |   |         |
| Wk4 (V06) vs. Wk8 (V07)   | 17                 | 0.1900 [0.0771, 0.8912] vs. 0.1142 [0.0404, 0.3422] | <0.0001 |
| Wk4 (V06) vs. Wk10 (V08)  | 17                 | 0.1900 [0.0771, 0.8912] vs. 2.7716 [0.9187, 9.1259] | <0.0001 |
| Wk4 (V06) vs. Wk16 (V10)  | 16                 | 0.1707 [0.0771, 0.8912] vs. 0.9596 [0.1715, 3.0402] | <0.0001 |
| Wk8 (V07) vs. Wk10 (V08)  | 17                 | 0.1142 [0.0404, 0.3422] vs. 2.7716 [0.9187, 9.1259] | <0.0001 |
| Wk8 (V07) vs. Wk16 (V10)  | 16                 | 0.1110 [0.0404, 0.3422] vs. 0.9596 [0.1715, 3.0402] | <0.0001 |
| Wk10 (V08) vs. Wk16 (V10) | 16                 | 2.8572 [0.9187, 9.1259] vs. 0.9596 [0.1715, 3.0402] | <0.0001 |